CH641349A5 - Disintegrable tablet containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane or one of its pharmaceutically acceptable salts - Google Patents
Disintegrable tablet containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane or one of its pharmaceutically acceptable salts Download PDFInfo
- Publication number
- CH641349A5 CH641349A5 CH1290478A CH1290478A CH641349A5 CH 641349 A5 CH641349 A5 CH 641349A5 CH 1290478 A CH1290478 A CH 1290478A CH 1290478 A CH1290478 A CH 1290478A CH 641349 A5 CH641349 A5 CH 641349A5
- Authority
- CH
- Switzerland
- Prior art keywords
- tablet
- composition according
- weight
- composition
- bicarbonate
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 5
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 title claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 21
- 239000000470 constituent Substances 0.000 claims description 12
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 11
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- -1 2-carboxy-chromone-5-yloxy Chemical group 0.000 claims description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 4
- 239000008187 granular material Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- RVMGXWBCQGAWBR-UHFFFAOYSA-N 4-oxo-1-benzopyran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC(=O)C2=C1 RVMGXWBCQGAWBR-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB53825/77A GB1595220A (en) | 1977-12-23 | 1977-12-23 | Tablets containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH641349A5 true CH641349A5 (en) | 1984-02-29 |
Family
ID=10469110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1290478A CH641349A5 (en) | 1977-12-23 | 1978-12-19 | Disintegrable tablet containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane or one of its pharmaceutically acceptable salts |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS5489016A (enExample) |
| AU (1) | AU523616B2 (enExample) |
| BE (1) | BE872918A (enExample) |
| CA (1) | CA1108992A (enExample) |
| CH (1) | CH641349A5 (enExample) |
| DE (1) | DE2855001A1 (enExample) |
| DK (1) | DK568278A (enExample) |
| FI (1) | FI783897A7 (enExample) |
| FR (1) | FR2412310A1 (enExample) |
| GB (1) | GB1595220A (enExample) |
| IE (1) | IE47539B1 (enExample) |
| IL (1) | IL56239A (enExample) |
| IT (1) | IT7831068A0 (enExample) |
| LU (1) | LU80721A1 (enExample) |
| NL (1) | NL7812344A (enExample) |
| NZ (1) | NZ189255A (enExample) |
| SE (1) | SE7813062L (enExample) |
| ZA (1) | ZA787155B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07116017B2 (ja) * | 1986-05-17 | 1995-12-13 | アース製薬株式会社 | 入浴剤 |
| GB9824604D0 (en) * | 1998-11-11 | 1999-01-06 | Hewlett Healthcare Limited | Treatment of allergic conditions |
| US20030035833A1 (en) * | 2000-12-06 | 2003-02-20 | Xiaorong He | Rapidly dispersing pharmaceutical composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2132521A1 (en) * | 1971-04-06 | 1972-11-24 | Sofrader Sa | Effervescent tablets prdn - by controlled drying in effervescent granule formation |
| GB1423985A (en) * | 1972-02-15 | 1976-02-04 | Fisons Ltd | Pharmaceutical compositions containing bischromonyloxy compounds |
| GB1517153A (en) * | 1974-11-30 | 1978-07-12 | Fisons Ltd | Naphthopyran-and benzodipyran-2-carboxylic acids and derivatives thereof |
| GB1570993A (en) * | 1976-05-21 | 1980-07-09 | Fisons Ltd | Pharmaceutical tablet formulation |
| GB1557082A (en) * | 1977-01-25 | 1979-12-05 | Fisons Ltd | Pharmaceutical mixture containing an antiinflammatory |
-
1977
- 1977-12-23 GB GB53825/77A patent/GB1595220A/en not_active Expired
-
1978
- 1978-12-18 AU AU42654/78A patent/AU523616B2/en not_active Expired
- 1978-12-18 IL IL56239A patent/IL56239A/xx unknown
- 1978-12-18 DK DK568278A patent/DK568278A/da not_active Application Discontinuation
- 1978-12-19 FI FI783897A patent/FI783897A7/fi unknown
- 1978-12-19 CH CH1290478A patent/CH641349A5/fr not_active IP Right Cessation
- 1978-12-19 SE SE7813062A patent/SE7813062L/xx unknown
- 1978-12-20 NZ NZ189255A patent/NZ189255A/en unknown
- 1978-12-20 ZA ZA00787155A patent/ZA787155B/xx unknown
- 1978-12-20 BE BE192444A patent/BE872918A/xx not_active IP Right Cessation
- 1978-12-20 IT IT7831068A patent/IT7831068A0/it unknown
- 1978-12-20 NL NL7812344A patent/NL7812344A/xx not_active Application Discontinuation
- 1978-12-20 DE DE19782855001 patent/DE2855001A1/de not_active Withdrawn
- 1978-12-21 JP JP15697478A patent/JPS5489016A/ja active Pending
- 1978-12-21 CA CA318,406A patent/CA1108992A/en not_active Expired
- 1978-12-21 IE IE2540/78A patent/IE47539B1/en unknown
- 1978-12-22 LU LU80721A patent/LU80721A1/xx unknown
- 1978-12-22 FR FR7836221A patent/FR2412310A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FI783897A7 (fi) | 1979-06-24 |
| DE2855001A1 (de) | 1979-07-05 |
| IL56239A (en) | 1983-02-23 |
| SE7813062L (sv) | 1979-06-24 |
| IE782540L (en) | 1979-06-23 |
| IE47539B1 (en) | 1984-04-18 |
| ZA787155B (en) | 1979-12-27 |
| FR2412310B1 (enExample) | 1982-12-31 |
| JPS5489016A (en) | 1979-07-14 |
| FR2412310A1 (fr) | 1979-07-20 |
| IT7831068A0 (it) | 1978-12-20 |
| AU523616B2 (en) | 1982-08-05 |
| IL56239A0 (en) | 1979-03-12 |
| LU80721A1 (fr) | 1979-09-07 |
| NZ189255A (en) | 1984-05-31 |
| BE872918A (fr) | 1979-06-20 |
| AU4265478A (en) | 1979-06-28 |
| CA1108992A (en) | 1981-09-15 |
| GB1595220A (en) | 1981-08-12 |
| DK568278A (da) | 1979-06-24 |
| NL7812344A (nl) | 1979-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2201217C2 (ru) | Таблетка с энтеросолюбильным покрытием и способ приготовления | |
| FI77371B (fi) | Foerfarande foer framstaellning av en kapsel, som innehaoller ett alkaliskt aemne och acetylsalicylsyra. | |
| UA72922C2 (uk) | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ | |
| RU2153337C2 (ru) | Таблетка парацетамола и домперидона с пленочным покрытием | |
| CN101596165B (zh) | 泮托拉唑钠肠溶微丸 | |
| IE53543B1 (en) | New oral dipyridamole preparations | |
| NL8500724A (nl) | Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan. | |
| WO2007106960A1 (en) | Controlled-release floating dosage forms | |
| MC1101A1 (fr) | Composition a activite retardee | |
| US5468503A (en) | Oral pharmaceutical preparation released at infragastrointestinal tract | |
| EA003736B1 (ru) | Лекарственная форма для перорального введения, содержащая бета-лактамный антибиотик | |
| JPH07112973B2 (ja) | イブプロフェン又はその塩を活物質とする可溶性の消炎性組成物及びその製造方法 | |
| ZA200006440B (en) | Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates. | |
| EP0942718A1 (fr) | Comprime de maleate de trimebutine pellicule | |
| JPH0354926B2 (enExample) | ||
| CH641349A5 (en) | Disintegrable tablet containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane or one of its pharmaceutically acceptable salts | |
| Ozer et al. | Studies on the masking of unpleasant taste of beclamide: Microencapsulation and tabletting | |
| JP3853358B2 (ja) | フシジン酸錠剤の製法 | |
| RU2130310C1 (ru) | Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для внутреннего применения | |
| JPS6320409B2 (enExample) | ||
| RU2694056C2 (ru) | Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления | |
| KR20010057578A (ko) | 아스코르브산 및 펙틴을 포함하는 조성물 | |
| JPH0478615B2 (enExample) | ||
| KR100700472B1 (ko) | 프로펜 함유 제약 혼합물 | |
| WO2007086846A1 (en) | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |